ZA200706389B - Compositions for immunizing against mycobacterium - Google Patents
Compositions for immunizing against mycobacteriumInfo
- Publication number
- ZA200706389B ZA200706389B ZA200706389A ZA200706389A ZA200706389B ZA 200706389 B ZA200706389 B ZA 200706389B ZA 200706389 A ZA200706389 A ZA 200706389A ZA 200706389 A ZA200706389 A ZA 200706389A ZA 200706389 B ZA200706389 B ZA 200706389B
- Authority
- ZA
- South Africa
- Prior art keywords
- antigen
- compositions
- against mycobacterium
- immunizing against
- vector expressing
- Prior art date
Links
- 241000186359 Mycobacterium Species 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 2
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/04—Uses of viruses as vector in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Techniques For Improving Reliability Of Storages (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0500102.9A GB0500102D0 (en) | 2005-01-05 | 2005-01-05 | Method for generating a memory t cell response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200706389B true ZA200706389B (en) | 2008-08-27 |
Family
ID=34179184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200706389A ZA200706389B (en) | 2005-01-05 | 2007-08-01 | Compositions for immunizing against mycobacterium |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7850979B2 (sl) |
| CN (2) | CN101115500A (sl) |
| AT (1) | ATE501727T1 (sl) |
| DE (1) | DE602006020679D1 (sl) |
| DK (1) | DK1833507T3 (sl) |
| ES (1) | ES2364698T3 (sl) |
| GB (1) | GB0500102D0 (sl) |
| PT (1) | PT1833507E (sl) |
| RS (1) | RS51815B (sl) |
| SI (1) | SI1833507T1 (sl) |
| UA (1) | UA93665C2 (sl) |
| ZA (1) | ZA200706389B (sl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE445638T1 (de) * | 1998-11-04 | 2009-10-15 | Isis Innovation | Tuberkulose diagnose test |
| US20100226998A1 (en) * | 2009-03-05 | 2010-09-09 | Ultradent Products, Inc. | Anti-viral and anti-microbial dental operative material and methods |
| WO2010132054A1 (en) * | 2009-05-13 | 2010-11-18 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens of mycobacterium tuberculosis |
| EA028924B1 (ru) * | 2010-12-21 | 2018-01-31 | Макс-Планк-Гезельшафт Цур Фёрдерунг Дер Виссеншафтен Е.В. | Применение рекомбинантной клетки микобактерии для создания вакцины против туберкулеза, рака мочевого пузыря, аутоиммунных заболеваний или проказы, где вакцина индуцирует выработку т-клеток, продуцирующих il-17 |
| EP2838990A4 (en) | 2012-04-16 | 2016-08-10 | Aeras Global Tb Vaccine Found | RECOMBINANT MYCOBACTERIUM FOR THE CODING OF A HEPARIN-BINDING HEMAGGLUTININE (HBHA) FUSION PROTEIN AND USES THEREOF |
| CN102732480A (zh) * | 2012-06-11 | 2012-10-17 | 中山大学 | N-乙酰半胱氨酸对中央记忆性t细胞的绝对数量在体外扩增上的应用 |
| CN118662620A (zh) * | 2023-03-15 | 2024-09-20 | 康希诺生物股份公司 | 一种肺结核疫苗及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| CN1596126A (zh) * | 2001-11-30 | 2005-03-16 | 埃西斯创新有限公司 | 疫苗 |
-
2005
- 2005-01-05 GB GBGB0500102.9A patent/GB0500102D0/en not_active Ceased
-
2006
- 2006-01-05 UA UAA200707950A patent/UA93665C2/ru unknown
- 2006-01-05 PT PT06700223T patent/PT1833507E/pt unknown
- 2006-01-05 RS RS20110238A patent/RS51815B/en unknown
- 2006-01-05 DE DE602006020679T patent/DE602006020679D1/de active Active
- 2006-01-05 US US11/813,397 patent/US7850979B2/en not_active Expired - Fee Related
- 2006-01-05 SI SI200631018T patent/SI1833507T1/sl unknown
- 2006-01-05 CN CNA2006800045010A patent/CN101115500A/zh active Pending
- 2006-01-05 ES ES06700223T patent/ES2364698T3/es active Active
- 2006-01-05 CN CN2011103023092A patent/CN102580070A/zh active Pending
- 2006-01-05 DK DK06700223.8T patent/DK1833507T3/da active
- 2006-01-05 AT AT06700223T patent/ATE501727T1/de active
-
2007
- 2007-08-01 ZA ZA200706389A patent/ZA200706389B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1833507T1 (sl) | 2011-07-29 |
| PT1833507E (pt) | 2011-06-27 |
| DE602006020679D1 (de) | 2011-04-28 |
| DK1833507T3 (da) | 2011-07-11 |
| RS51815B (en) | 2011-12-31 |
| UA93665C2 (ru) | 2011-03-10 |
| ES2364698T3 (es) | 2011-09-12 |
| ATE501727T1 (de) | 2011-04-15 |
| US7850979B2 (en) | 2010-12-14 |
| GB0500102D0 (en) | 2005-02-09 |
| CN101115500A (zh) | 2008-01-30 |
| US20080226678A1 (en) | 2008-09-18 |
| CN102580070A (zh) | 2012-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006072787A8 (en) | Compositions for immunizing against mycobacterium | |
| Khan | DNA vaccines: roles against diseases | |
| ZA200706389B (en) | Compositions for immunizing against mycobacterium | |
| Dietrich et al. | Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity | |
| Delany et al. | Vaccines for the 21st century | |
| da Costa et al. | Tuberculosis vaccines–state of the art, and novel approaches to vaccine development | |
| Schoen et al. | Bacteria as DNA vaccine carriers for genetic immunization | |
| Roohvand et al. | Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities | |
| GB2434367A (en) | Improved vaccines | |
| TW200637910A (en) | Recombinant BCG strains with enhanced ability to escape the endosome | |
| MX2023006203A (es) | Vacunas novedosas contra el virus de zika. | |
| MXPA05013973A (es) | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. | |
| BR0311995A (pt) | Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso | |
| EP2385059A3 (en) | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| WO2006095330A3 (en) | Methods and immunogenic cell preparations for treating antigen-associated diseases | |
| WO2002061113A3 (en) | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation | |
| SG158154A1 (en) | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes | |
| WO2008057235A3 (en) | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | |
| Matsuo et al. | Mycobacterium bovis Bacille Calmette‐Guérin as a Vaccine Vector for Global Infectious Disease Control | |
| Excler et al. | Lessons from HIV-1 vaccine efficacy trials | |
| WO2004043399A3 (en) | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines | |
| Soundarya et al. | Current trends in tuberculosis vaccine | |
| WO2003085098A3 (en) | Identification of virulence associated regions rd1 and rd5 enabling the development of improved vaccines of m. bovis bcg and m. microti | |
| Stanberry et al. | Vaccines of the future | |
| Xiao-wen et al. | Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting |